An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 3, 2018

Primary Completion Date

March 31, 2020

Study Completion Date

July 2, 2020

Conditions
Candidemia
Interventions
DRUG

APX001

APX001

Trial Locations (29)

1000

Institut Jules Bordet,Service De Microbiologie, Brussels

1070

Hopital Erasme, Brussels

5530

Mont-Godinne University Hospital, Yvoir

27710

Duke University Hospital Medical Center, Durham

30901

Augusta University (Georgia Regents University), Augusta

35233

University of Alabama at Birmingham School of Medicine, Birmingham

35249

University of Alabama at Birmingham (UAB), Birmingham

52621

Infectious Diseases Unit,Sheba Medical Center, Tel Litwinsky

60637

University of Chicago, Chicago

63110

Washington University, St Louis

77030

University of Texas- Health Science Center and Medical School at Houston, Houston

95616

University of California, Davis, Davis

95817

University of California-Davis Medical Center, Sacramento

3109601

Infectious Diseases Unit, Rambam Medical Center, Haifa

6423906

Infectious Diseases Unit, Tel Aviv

Unknown

Institut Jules Bordet, Brussels

Universite Libre de Bruxelles (ULB) - Hopital Erasme, Brussels

CHU de Charleroi - Hopital Civil Marie Curie, Lodelinsart

University Hospital Mont-Godinne, Yvoir

Klinik I fur Innere Medizin- Uniklinik Koln, Cologne

University Hospital Heidelberg, Heidelberg

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz - III. Medizinische Klinik Haematologie/Onkologie, Mainz

Rambam Medical Center, Haifa

Sourasky Medical Center, Tel Aviv

Sheba Medical Center, Tel Litwinsky

Hospital Universitario Mutua de Terrassa, Terrassa

Hospital General Universitario de Alicante, Alicante

Hospital VLL D Hebron, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Basilea Pharmaceutica

INDUSTRY

NCT03604705 - An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia | Biotech Hunter | Biotech Hunter